Collegium Pharmaceutical (COLL) Cost of Revenue (2016 - 2026)

Collegium Pharmaceutical's Cost of Revenue history runs 11 years deep, the most recent figure standing at $20.8 million for Q1 2026.

• On a quarterly basis, Cost of Revenue fell 74.14% year-over-year to $20.8 million in Q1 2026; TTM through Mar 2026 was $146.7 million, a 23.21% decrease from a year earlier, with the FY2025 full-year figure at $3.1 million, down 96.56% from the prior year.
• Cost of Revenue declined to $20.8 million in Q1 2026 per COLL's latest filing, from $21.6 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $80.4 million in Q1 2025 and bottomed at $20.0 million in Q2 2024.
• The 5-year median for Cost of Revenue is $29.9 million (2023), against an average of $41.1 million.
• Across the five-year window, Cost of Revenue soared 347.48% in 2022 and sank 74.14% in 2026, its largest moves.
• Year by year, Cost of Revenue stood at $37.6 million in 2022, then slumped by 45.14% to $20.6 million in 2023, then soared by 36.84% to $28.2 million in 2024, then decreased by 23.38% to $21.6 million in 2025, then dropped by 3.69% to $20.8 million in 2026.
• Per Business Quant, the three latest COLL Cost of Revenue figures stand at $20.8 million (Q1 2026), $21.6 million (Q4 2025), and $24.7 million (Q3 2025).